Gilead spends $100M to partner with Assembly Bio on antivirals for hepatitis, herpes - Endpoints News
endpts.comSubmitted by endpointsnews6292 in business
Gilead is pouring significant cash into a startup that’s seen several setbacks over the years while promising a hefty helping of biobucks down the road if it can advance a handful of antiviral candidates. The partnership with Assembly Biosciences announced Tu…